PHILADELPHIA – Hao Wu, PhD
, an assistant professor of Genetics in the Perelman School of Medicine at the University of Pennsylvania
has received a New Innovator Award from the National Institutes of Health (NIH). These awards provide each recipient $1.5 million over five years to pursue high-risk, high-reward investigations that could have implications for human health. Wu’s grant is among 89 announced last week “to highly creative and exceptional scientists with bold approaches to major challenges in biomedical research,” according to the NIH announcement
The New Innovator Award, established in 2007, supports unusually innovative research from early career investigators who are within 10 years of their final degree or clinical residency and have not yet received a research project grant or equivalent NIH grant. For 2017, NIH granted 55 New Innovator awards, as well as 12 Pioneer awards, 8 Transformative Research awards, and 11 Early Independence awards, all part of the NIH High-Risk, High-Reward Research program,
“I continually point to this program as an example of the creative and revolutionary research NIH supports,” said NIH Director Francis S. Collins, MD, PhD. “The quality of the investigators and the impact their research has on the biomedical field is extraordinary.”
Wu, also a core member of the Epigenetics Institute, came to Penn in 2016. His lab develops profiling and editing tools to investigate molecular interactions between environmental factors such as oxygen levels in tissues and the epigenome, a battery of chemical marks that control gene expression. Oxygen acts as a critical helper cofactor for many key epigenetic enzymes.
Recent studies suggest that cells can rapidly adapt to changing environmental inputs by modifying their epigenome and therefore which genes are expressed. Wu’s lab is interested in investigating the molecular underpinnings regulating this interaction and its relationship to developmental processes and human diseases.
Wu’s new grant will fund his study of how the epigenome of heart muscle cells respond and adapt to changing environmental oxygen levels. These heart cells can proliferate and therefore possess regenerative potential in the oxygen-poor environment of a developing embryo before birth but rapidly lose such potential in the oxygen-rich environment of newborn mice or humans that have taken their first breath of air. Better understanding of the molecular program that promotes proliferation of heart muscle cells in the embryos may inform therapeutic approaches to treat adult heart disease.
He proposes to develop single-cell profiling methods and “oxygen-sensing” epigenome editing enzymes to learn how to rewire the epigenome of mammalian heart muscle cells for the purpose of adult heart regeneration. “Armed with these new tools, we will have the ability to observe and actively manipulate the interaction between environmental inputs and the epigenome ‘on demand’, providing fundamentally new opportunities to study the environment-epigenome interaction involved in a broad array of biological and pathological processes,” Wu said.
Wu received his bachelor’s degree in Biological Sciences from Tsinghua University before moving to the University of California, Los Angeles, where he earned his PhD in Molecular Pharmacology. He worked in the laboratories of Yi Zhang and Kenneth Chien at Harvard University for his postdoctoral training where he developed and applied new methods for investigating gene regulatory roles of novel DNA modifications in pluripotent stem cells and during heart development. He was the recipient of a Jane Coffin Child Postdoctoral Fellowship and a Pathway to Independence Award from the NIH.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System, which together form a $8.6 billion enterprise.
The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $494 million awarded in the 2019 fiscal year.
The University of Pennsylvania Health System’s patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center—which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report—Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is powered by a talented and dedicated workforce of more than 43,900 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2019, Penn Medicine provided more than $583 million to benefit our community.